Left for dead af­ter a fail­ure in neu­ro­path­ic pain, Aptinyx latch­es on­to pos­i­tive PhII da­ta in PTSD

Al­most two years af­ter a Phase II fail sent in­vestors run­ning for the hills, Aptinyx $AP­TX may have found a new life­line.

The Evanston, IL-based biotech, which fo­cus­es on brain and cen­tral ner­vous sys­tem dis­or­ders, an­nounced pos­i­tive Phase II da­ta in post-trau­mat­ic stress dis­or­der Mon­day af­ter­noon with one of its NM­DA re­cep­tor mod­u­la­tors. Armed with the topline ef­fi­ca­cy and safe­ty re­sults, Aptinyx now plans to be­gin a piv­otal study some­time in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER